Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function
ConclusionsThe analysis shows that terlipressin is a cost-effective treatment due to its higher efficacy and administration in the non-ICU setting. Terlipressin is a value-based treatment option for appropriate adults with HRS with rapid reduction in kidney function.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cirrhosis | Dialysis | Drugs & Pharmacology | Intensive Care | Urology & Nephrology | USA Health